MaxCyte IPO Presentation Deck

We Are Just Beginning Our Forward Momentum Impact July 2021 MaxCyte Scalable GT Transfection Scientific System Foundation 1999 Cell Therapy M MaxCyte 2000 FDA Master File 2002 MaxCyte Scalable STX Transfection System VLX Large-Scale Transfection System (prototype) 2005 2008 London Stock Exchange AIM Drug Discovery Listing LSE: AIM March 2016 LON: MXCT 2016 CONFIDENTIAL MaxCyte ATX Gen 2 Transfection System 2018 Processing Assembly Portfolio Expansion MaxCyte EXPERT Platform expert 2019 M MaxCyte 13 Strategic Platform Licenses signed since 2017 65 FTES (19 w/ PhD degrees) 20+ field sales and application scientists* *As of March 31, 2021 2021

View entire presentation